HBK Sorce Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

HBK Sorce Advisory’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$987K	Buy	6,448 +529	+9%	+$71.5K	0.02%	261
2026 Q1	$797K	Sell	5,919 -53	-0.9%	-$6.62K	0.02%	285
2025 Q4	$750K	Buy	5,972 +510	+9%	+$58.5K	0.02%	285
2025 Q3	$592K	Buy	5,462 +21	+0.4%	+$1.89K	0.01%	321
2025 Q2	$451K	Sell	5,441 -351	-6%	-$28K	0.01%	362
2025 Q1	$470K	Buy	5,792 +1,310	+29%	+$117K	0.01%	353
2024 Q4	$404K	Buy	4,482 +279	+7%	+$27K	0.01%	385
2024 Q3	$415K	Sell	4,203 -119	-3%	-$11.7K	0.01%	382
2024 Q2	$401K	Sell	4,322 -216	-5%	-$19.4K	0.01%	371
2024 Q1	$431K	Buy	4,538 +113	+3%	+$10.5K	0.02%	368
2023 Q4	$395K	Buy	4,425 +267	+6%	+$19.8K	0.02%	363
2023 Q3	$304K	Buy	4,158 +37	+0.9%	+$2.96K	0.01%	417
2023 Q2	$343K	Sell	4,121 -25	-0.6%	-$2.09K	0.01%	409
2023 Q1	$316K	Sell	4,146 -3,450	-45%	-$286K	0.01%	423
2022 Q4	$631K	Buy	7,596 +3,759	+98%	+$304K	0.02%	371
2022 Q3	$304K	Buy	3,837 +1,006	+36%	+$84.8K	0.02%	361
2022 Q2	$210K	Buy	2,831 +308	+12%	+$23.1K	0.02%	420
2022 Q1	$227K	Buy	2,523 +175	+7%	+$16.2K	0.01%	478
2021 Q4	$263K	Buy	2,348 +3	+0.1%	+$362	0.01%	489
2021 Q3	$295K	Sell	2,345 -60	-2%	-$7.73K	0.02%	442
2021 Q2	$326K	Buy	2,405 +10	+0.4%	+$1.31K	0.02%	427
2021 Q1	$325K	Buy	2,395 +222	+10%	+$33.2K	0.02%	383
2020 Q4	$306K	Buy	2,173 +100	+5%	+$12.8K	0.02%	368
2020 Q3	$231K	Buy	+2,073	New	+$232K	0.02%	390
2018 Q4	–	Sell	-2,331	Closed	-$224K	–	423
2018 Q3	$224K	Buy	2,331 +44	+2%	+$4.27K	0.03%	356
2018 Q2	$218K	Buy	+2,287	New	+$210K	0.03%	353

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

HBK Sorce Advisory's XBI Position: Q2 2026 in Review

HBK Sorce Advisory increased its State Street SPDR S&P Biotech ETF (XBI) stake by 8.9% in Q2 2026, buying an estimated $71.5K and bringing the position to 6,448 shares worth $987K. The position accounts for 0.02% of the portfolio, ranked #261.

HBK Sorce Advisory first reported a position in XBI in Q2 2018 and has held it in 26 quarters since. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

HBK Sorce Advisory held 6,448 shares of State Street SPDR S&P Biotech ETF worth $987K as of Q2 2026.
HBK Sorce Advisory bought 529 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $71.5K.
State Street SPDR S&P Biotech ETF made up 0.02% of HBK Sorce Advisory's portfolio in Q2 2026, its #261 holding.
HBK Sorce Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and has held it in 26 quarters since.
936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.